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CBackground: Decision analytic models in health care require baseline
health-related quality of life data to accurately assess the benefits of
interventions. The use of inappropriate baselines such as assuming the
value of perfect health (EQ-5D  1) for not having a condition may
verestimate the benefits of some treatment and thus distort policy
ecisions informed by cost per quality adjusted life years thresholds.
bjective: The primary objective was to determine if data from the gen-
ral population are appropriate for baseline health state utility values
HSUVs) when condition specific data are not available. Methods: Data
rom four consecutive Health Surveys for England were pooled. Self-
eported health status and EQ-5D data were extracted and used to
enerate mean HSUVs for cohorts with or without prevalent health
onditions. These were compared with mean HSUVs from all respon-
ents irrespective of health status. Results: More than 45% of respon-
ents (n  41,174) reported at least one condition and almost 20% re- O
ecis
al So
doi:10.1016/j.jval.2010.10.029orted at least two. Our results suggest that data from the general
opulation could be used to approximate baseline HSUVs in some analy-
es, but not all. In particular, HSUVs from the general population would
ot be an appropriate baseline for cohortswhohave just one condition. In
hese instances, if condition specific data are not available, data from
espondents who report they do not have any prevalent health condition
aybemore appropriate. Exploratory analyses suggest thedecrement on
ealth-related quality of life may not be constant across ages for all con-
itions and these relationships may be condition specific. Additional re-
earch is required to validate our findings.
eywords: age-adjusted, baseline, EQ-5D, health state utility values,
uality of life.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Agencies such as the UK National Institute for Health and Clinical
Excellence (NICE) produce national guidance on the provision of
new health technologies, and their recommendations are informed
by reviewsof clinical and economic evidence. To facilitate consistent
reimbursement recommendations across all disease areas, interven-
tions are appraised using a decision rule based on the incremental
cost per quality-adjusted life year (QALY). The costs perQALY results
are estimated using decision analytic models that describe the clin-
ical pathway of health conditions or systemsmathematically.
Analytic models frequently compare the benefits of treatments
that have the potential to alleviate a health condition or avoid a clin-
ical event. Conditions and events are described by health states in
the models and the health related quality of life (HRQoL) or health
state utility values (HSUV) associated with these are generally ob-
tained from clinical trials or observational studies. The baselineHRQoL
usedtorepresent theHSUVsfor individualswithout theseconditionsor
events is equally relevant as these data are used to assess the HRQoL
gain in alleviating or avoiding the condition or event.
Ideally the baseline HSUVswould be derived frompeople with-
out specific condition(s) using the definitions of health states in
themodel. However, these data are rarely available and a baseline
* Address correspondence to: Roberta Ara, Health Economics and D
heffield S1 4DA, UK.
E-mail address: r.m.ara@sheffield.ac.uk.
1098-3015/$36.00 – see front matter Copyright © 2011, Internation
Published by Elsevier Inc.of full health is commonly assumed [1]. Because the average per-
son still has other health problems, this assumption overesti-
mates the benefits of treatment [2,3] and it has been suggested
that on average, a treatment will increase HRQoL to the same level
as persons without the condition [4]. The baseline HSUVs used in
decision models have important consequences as these data
could distort a policy decision based on a cost per QALY threshold
thus undermining efficient resource allocation [5].
When condition specific baseline data are not available, one so-
lutionhasbeen touseage-adjustedHSUVsobtained fromthegeneral
population (irrespective of health condition) [1,2]. These data will
include individuals with the condition of interest; hence, an ele-
ment of double counting is inevitable. However, unless the prev-
alence of the health condition is high or the affect on HRQoL is
substantial, intuitively one would expect the HRQoL of an average
person without a particular health condition to be similar to the
HRQoL of an average person of a similar age in the general popu-
lation. Researchers have shown that in cardiovascular disease
(CVD) the cost per QALY results are of a similar magnitude when
estimated using either a baseline from the general population or a
baseline from respondents with no history of CVD [5].
The primary objective of our study is to determine if this find-
ing generalizes to other conditions and thus, if data from the gen-
ion Science, ScHARR, The University of Sheffield, 30 Regent Street,
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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models. Specifically, we compare the HRQoL for subgroups who
have a particular prevalent health condition (irrespective of other
conditions) with the HRQoL from similar-aged subgroups who do
not have the condition (irrespective of other health conditions),
and the HRQoL from similar-aged subgroups irrespective of health
status (i.e., the general population). As a secondary analysis, we
compare theHRQoL for subgroupswhohave just oneparticularprev-
alent health condition with the HRQoL from similar-aged subgroups
who do not have any condition, and the HRQoL from similar-aged
subgroups irrespective of health status (i.e., the general population).
Methods
Data
WeusedHRQoL data and information on health status collected in
the Health Survey for England (HSE) [6]. The HSE is an annual
survey conducted on randomly selected samples of the population
living in private households in England. For this study, we pooled
data collected during the 2003, 2004, 2005, and 2006 surveys. Infor-
mation on health status was obtained from responses to the fol-
lowing question: “Do you have any long-standing illness, disabil-
ity, or infirmity? By long-standing I mean anything that has
troubled you over a period of time, or that is likely to affect you
over a period of time?” Respondents provided details for a maxi-
mum of six long-standing illnesses and responses were subse-
quently coded into 39 different health conditions. Two additional
codes: “unclassifiable” and “complaint no longer present” were
treated as no condition in our analyses.
HRQoL information was collected using the widely used ge-
neric questionnaire known as the EQ-5D [7]. The EQ-5D contains
five attributes of health status, including mobility, self-care, usual
activities, pain/discomfort, and anxiety/depression. Each attribute
is measured by a question with three possible responses: no prob-
lem, some problems, or severe problem. The combination of all
possible responses leads to 243 (35) distinct health states. A ran-
dom sample of the UK general public valued a sample of these
health states using time trade-off techniques [7]. The resulting
algorithm, which was used to calculate HSUVs for our study, pro-
duces a range of 0.59 to 1, where 1 represents perfect health, 0
represents death, andnegative values represent health states con-
sidered to be worse than death.
Analysis
Generally patients in decision analytic models are defined to
match the demographic characteristics of patients who would re-
ceive the intervention under evaluation in clinical practice. Con-
sequently a typical patient will have concurrent health conditions
and for older aged cohorts, a substantial proportion of patientswill
have additional prevalent health conditions. However, the effec-
tiveness and HRQoL evidence used to assess the benefits of treat-
ments may be derived from studies using strict recruitment crite-
ria and patientswith comorbidities can be excluded from these. As
the baseline needs to reflect the definitions and data used in the
model, we perform a series of analyses as described below.
1. The primary analyses test whether data from the general pop-
ulation can be used as the baseline HRQoL when data from
cohorts with a specific health condition (irrespective of other
health conditions) are used to assess the benefits of treatment.
We compare mean EQ-5D scores for these subgroups with
mean EQ-5D scores from respondents of a similar age who did
not have the specific health condition, and respondents of a
similar age irrespective of health status (i.e., the general popu-
lation). p2. The secondary analyses test whether data from the general pop-
ulation can be used as the baseline HRQoL when data from co-
hortswith a singlehealth conditionareused to assess thebenefits
of treatment. We compare mean EQ-5D scores for these sub-
groupswithmeanEQ-5D scores from respondents of a similar age
who do not have any health conditions and respondents of a sim-
ilar age irrespective of health status (i.e., the general population).
3. Exploratory analyses were also performed to test if the decre-
ments on HRQoL for cohorts with a specific health condition
(irrespective of other health conditions) are comparable to the
decrements for cohortswith the single specific health condition
(and no other condition), and if the decrements on HRQoL are
constant across age.
All analyses were performed in STATA (version 11, 2010, Stata-
Corp, College Station, TX). The analyses were weighted using the
individual level self-administered questionnaire weights [6]. Us-
ing the minimal important difference for the EQ-5D (0.074) as a
benchmark [8] and assuming SD 0.20 in EQ-5D scores, we used
subgroups ofmore than 64 (256) respondents for having the power
to detect a mean difference of 0.10  0.05 with 80% power and 5%
two-sided significance. Statistical significance for the weighted
mean EQ-5D scores was assessed using the 95% confidence inter-
vals (CI) of the mean whereby if the CIs do not overlap there is a
statistically significant difference between the groups [9].
Results
Of the 41,174 respondents who completed the EQ-5D question-
naire, 44.5% (18,302 of 41,174) were male, and the mean age was
48.6 18.5 years formales and 48.5 19.0 years for females. 54.5%
(22,449 of 41,174) reported they did not have a history of a health
condition, 26.1% (10,762 of 41,174) reported just one condition, and
19.3% (7,963 of 41,174) reported at least two conditions. The most
prevalent condition (Table A1 appendix available at: doi:10.1016/
j.jval.2010.10.029) was “arthritis/rheumatism/fibrositis” at 10.1%
(4,145 of 41,174) of the sample followed by “hypertension/high
blood pressure” at 7.7% (3,172 of 41,174). Prevalence of comorbid
health conditions varied by primary health condition and by age.
The proportion of respondents with more than one health condi-
tion ranged from 84.2% (123 of 146) of respondents with “other
bladder problems/incontinence” to 54.0% (1325 of 2452) of respon-
dents with asthma. For respondents (n  4212) aged 40 years or
youngerwho reported at least one health condition, just 22.2%had
at least one other condition whereas 57.4% of respondents (n 
1638) aged 40 years or younger who reported at least one health
condition had at least one other condition.
The mean EQ-5D for all respondents (n  41,174) was 0.868
(range 0.594 to 1). Respondents (n  22,449) who reported no
health condition had a mean EQ-5D of 0.949 (range 0.371 to 1),
whereas respondents who reported one or more than one health
condition had mean EQ-5D scores of 0.821 (range 0.594 to 1) and
0.654 (range 0.594 to 1), respectively.
Primary analyses
With the exception of respondents who had a history of hayfever
(n 416), all mean EQ-5D scores for respondents who reported they
ad a specific health condition irrespective of whether they also had
ther health conditions (Table 1 and online appendix available at:
oi:10.1016/j.jval.2010.10.029) were lower than the mean EQ-5D
cores for the subgroups who either did not have the condition or
he subgroups irrespective of health status. Four of the 39 subgroups
ad 64 respondents and were not assessed in terms of significant
ifferences in mean scores. Because the confidence intervals of the
ean EQ-5D scores did not overlap for 27/35 pairs when comparing
ith subgroups without the condition and 26 of 35 pairs when com-
aring with subgroups irrespective of health condition, the differ-
onde
541V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 3 9 – 5 4 5enceswere significant at P 0.05. Comparing themeanEQ-5D scores
for respondents not affected by a condition with the corresponding
mean scores for respondents irrespective of health condition, the
confidence intervals of the paired mean scores overlapped.
These data can be used to assess the average absolute or rela-
tive effect on HRQoL compared to an average person of a similar
age who does not have the named condition, or an average person
of a similar age irrespective of health status. For example, the
condition stroke/cerebral hemorrhage/cerebral thrombosis pro-
duced the largest average decrement on HRQoL compared to the
subgroup who did not have the condition (absolute 0.287, relative
35%) and the subgroup from the general population (absolute
0.282, relative 34%). When compared to subgroups without the
health condition, andwhen compared to subgroups irrespective of
health status, 31 of 35 of the differences in mean EQ-5D scores for
the groups with 64 respondents were greater than the minimal
important difference ( 0.074 ) for the EQ-5D [8].
Secondary analyses
For the subgroups who reported they had a single specific health
condition compared to subgroups of a similar age who reported no
health condition, with the exception of respondents who had a his-
tory of hayfever (n 186) and respondentswhohad a history of poor
hearing/deafness (n 146), allmean EQ-5D scoreswere lower for the
subgroupswith the condition (Table 2 and online appendix available
at: doi:10.1016/j.jval.2010.10.029). Ten of the 39 subgroups had 64
respondents hence were not assessed in terms of significant differ-
ences in mean scores. Of the remaining 29 pairs compared to sub-
groupswho reported no condition, as the confidence intervals of the
Table 1 – Primary analyses for the 10 largest subgroups: co
health condition (plus any other health condition), respond
respondents of a similar age irrespective of health status.
Health condition Mean
age
Respondents affected
by the health condition
(and any other health
condition)
Resp
affe
n Mean
EQ-5D
95% CI of
the mean
n M
E
Arthritis/rheumatism/
fibrositis
62.9 4145 0.597 (0.584, 0.609) 436
Asthma 44.2 2452 0.797 (0.779, 0.814) 674
Back problems/slipped
disc/spine/neck
50.0 2484 0.649 (0.632, 0.666) 615
Diabetes including
hyperglycemia
60.4 1772 0.714 (0.695, 0.731) 592
Heart attack/angina 68.5 929 0.628 (0.602, 0.653) 569
Hypertension/high blood
pressure
62.3 3172 0.777 (0.765, 0.788) 451
Mental illness/anxiety/
depression/nerves
45.5 1332 0.606 (0.585, 0.626) 645
Other endocrine/metabolic
diseases
56.4 1566 0.771 (0.747, 0.793) 655
Other heart problems 64.0 1349 0.672 (0.649, 0.694) 496
Other problems of bones/
joints/muscles
54.9 2526 0.642 (0.628, 0.656) 627
Absolute difference is the absolute difference inmean EQ-5D score co
by the health condition.
All confidence intervals (CIs) for mean EQ-5D overlap (P  0.05) whe
irrespective of health status.
Corresponding data for the full set of subgroups are available in the
* CIs for mean EQ-5D do not overlap (P  0.05) when comparing resp
† CIs for mean EQ-5D do not overlap (P  0.05) when comparing respmean EQ-5D scores did not overlap for 24 comparisons, the differ-enceswere significant at P 0.05.When comparing themean EQ-5D
scores for subgroups with a single health condition with subgroups
of a similar age irrespective of health status (i.e., general population),
of the 29 subgroups involving more than 64 respondents, the mean
scoresweregreater for13of thesubgroupswithasingle condition.As
the CIs for the mean EQ-5D scores did not overlap for eight of the 13
pairs, these differences were statistically significant (P  0.050). For
the remaining 16/29 subgroups with mean EQ-5D scores smaller than
those of similar aged subgroups irrespective of health status, the CIs of
themean EQ-5D scores did not overlap for 5/16 comparisons (P 0.05).
These data can be used to assess the average absolute or rela-
tive effect onHRQoL for a single condition in isolation compared to
an average person of a similar age who does not have any condi-
tion, or an average person of a similar age irrespective of health
status. For example the condition stroke/cerebral haemorrhage/
cerebral thrombosis produced the second largest average decre-
ment on HRQoL compared to the subgroup who had no condition
(absolute 0.254, relative 27%) and the subgroup from the general
population (absolute 0.106, relative 13%). When compared to sub-
groups without a health condition, 17 of 29 of the differences in
mean EQ-5D scores were greater than the minimal important dif-
ference (0.074) for the EQ-5D,whereas just 9 of 29 of the differences
were greater than the minimal important difference when com-
pared to the subgroups irrespective of health status [8].
Exploratory analyses
1. Comparing average decrements on HRQoL for cohorts with a
specific health condition (irrespective of other health condi-
ring mean EQ-5D scores for respondents subgrouped by
of a similar age without the health condition, and
ents of a similar age not
by the health condition
Respondents of a similar age
irrespective of health status
(i.e., general population)
95% CI of
the mean
Absolute
difference
n Mean
EQ-5D
95% CI of
the mean
Absolute
difference
(0.836, 0.888)* 0.265 538 0.812 (0.785, 0.839)† 0.215
(0.873, 0.907)† 0.093 714 0.885 (0.868, 0.902)† 0.088
(0.870, 0.905)† 0.239 668 0.866 (0.847, 0.885)† 0.217
(0.823, 0.866)† 0.131 628 0.841 (0.819, 0.862)† 0.127
(0.802, 0.850)† 0.198 603 0.822 (0.798, 0.846)† 0.194
(0.787, 0.835) 0.035 522 0.811 (0.788, 0.832) 0.034
(0.861, 0.894)† 0.272 682 0.856 (0.836, 0.876)† 0.250
(0.797, 0.861)† 0.059 696 0.821 (0.790, 0.852) 0.050
(0.771, 0.831)† 0.130 528 0.795 (0.765, 0.824)† 0.123
(0.833, 0.874)† 0.212 696 0.821 (0.790, 0.852)† 0.179
ed to themean EQ-5D score for the subgroup of respondents affected
paring: respondents not affected by the condition vs. respondents
Appendix.
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542 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 3 9 – 5 4 5just the single specific health condition. In 14 of the 39 condi-
tions, the average decrements on HRQoL were more than
halved for the subgroups with just the one health condition (vs.
subgroups with no condition) compared to the average decre-
ments on HRQoL for the subgroups with the same condition
irrespective of other conditions (vs. subgroups without the spe-
cific condition irrespective of other conditions). For example
the average relative decrement was 2% for respondents (n 
1127) with just asthma when compared to respondents of a
similar age without any health condition versus an average rel-
ative decrement of 10% for respondents (n 2452) with asthma
and any other health conditionwhen compared to respondents
of a similar age without asthma. These data suggest comorbidi-
ties impose an additional decrement on HRQoL and the impli-
cation of this should be considered on an individual basis when
calculating decrements attributed to the alleviation of condi-
tions or avoidance of clinical events in economic models.
. Comparing decrements on HRQoL across age groups. Using the
full data set, HRQoL decreased by age (Fig. 1) in general irrespec-
tive of the number of health conditions. The rate of decrease in
HRQoL by age was greatest in respondents aged over 65 years.
Comparing the mean EQ-5D scores for the youngest and oldest
aged cohorts subgroupedbyhealth status, the reduction inHRQoL
was greatest for respondents with at least one health condition.
Potential trends in decrements inHRQoL by age for the individual
ealth conditions were assessed visually by plotting mean EQ-5D
cores for age and health condition stratified subgroups together
ith the average absolute and relative decrements (Fig. 2 [Fig. A2 and
Table 2 – Secondary analyses for the 10 largest subgroups,
health condition, respondents of a similar age with no hea
health status.
Health condition Mean
age
Respondents affected by
the one health condition
(and no other health
condition)
n Mean
EQ-5D
95% CI of
the mean
Arthritis/rheumatism/
fibrositis
60.1 1358 0.685 (0.662, 0.706) 2
Asthma 37.6 1127 0.931 (0.922, 0.939) 5
Back problems/slipped
disc/spine/neck
45.5 1106 0.745 (0.727, 0.761) 4
Diabetes including
hyperglycemia
55.2 537 0.898 (0.883, 0.912) 3
Hypertension/high blood
pressure
59.8 974 0.916 (0.903, 0.928) 2
Mental illness/anxiety/
depression/nerves
40.6 541 0.709 (0.685, 0.733) 5
Other endocrine/metabolic
diseases
48.3 422 0.924 (0.909, 0.937) 3
Other heart problems 58.2 366 0.822 (0.781, 0.862) 2
Other problems of bones/
joints/muscles
48.9 942 0.731 (0.709, 0.753) 3
Other problems of
nervous system
48.2 336 0.695 (0.663, 0.726) 3
Abs diff is the absolute difference in mean EQ-5D score compared t
health condition.
All confidence intervals (CIs) for mean EQ-5D do not overlap (P  0.05
irrespective of health status.
Corresponding data for the full set of subgroups are available in the
* CIs for mean EQ-5D do not overlap (P  0.05) when comparing resp
† CIs for mean EQ-5D do not overlap (P  0.05) when comparing respig. A3 supplied in the Appendix available at: doi:10.1016/j.jval.010.10.029]). Due to small numbers in the age stratified data, these
xploratory analyses were performed for the most prevalent health
onditions only, and the data were compared to respondents who
id not have the relevant condition. For the cohort (n  2484) with
ack problems/slipped disc/spine/neck plus any other health condi-
ion, the average relative decrement on HRQoL compared to respon-
ents without the condition increased by age up to age 80 years (Fig.
a). This trendwas also visible in the cohort (n 1106)with just back
roblems/slipped disc/spine/neck (Fig. 2b) when compared to re-
pondentswith no health condition. The age stratified average abso-
ute decrements (range 0.19 to 0.29) were similar for the cohortswith
r without comorbid health conditions. Compared to the respon-
entswithout the condition, as theCIs for themeanEQ-5Dscoresdid
ot cross, all the age-stratified decrements were statistically signifi-
ant at the 95% level.
Conversely, for the cohort (n  3172) with hypertension/high
lood pressure/blood plus any other condition the relative decre-
ent on HRQoL compared to respondents without the condition
ecreased by age with the largest effects observed in respondents
ged under 60 years (Appendix, Fig. A1a available at: doi:10.1016/
.jval.2010.10.029). The average effect on HRQoLwasmuch smaller
cross all age groups for the cohort with just hypertension/high
lood pressure/blood (n  974) compared to the average effect on
RQoL for the cohort with hypertension/high blood pressure/blood
nd any other health condition (Appendix, Fig. A1b available at: doi:
0.1016/j.jval.2010.10.029).
For the cohort (n  4145) with arthritis/rheumatism/fibrositis
plus any other health condition, the average relative decrement on
paring mean EQ-5D score for respondents with a single
ondition, and respondents of a similar age irrespective of
ondents of a similar age
th no health condition
Respondents of a similar age
irrespective of health status
(i.e., general population)
Mean
Q-5D
95% CI of
the mean
Abs
diff
n Mean
EQ-5D
95% CI of
the mean
Abs
diff
0.936 (0.918, 0.953)* 0.251 628 0.841 (0.819, 0.862)† 0.156
0.953 (0.943, 0.962)* 0.022 794 0.903 (0.889, 0.916)† 0.028
0.952 (0.942, 0.960)* 0.207 736 0.879 (0.863, 0.895)† 0.134
0.952 (0.937, 0.965)* 0.054 670 0.835 (0.813, 0.856)† 0.063
0.936 (0.918, 0.953) 0.020 628 0.841 (0.819, 0.862)† 0.075
0.955 (0.946, 0.964)* 0.246 826 0.877 (0.856, 0.897)† 0.168
0.948 (0.934, 0.960) 0.024 647 0.858 (0.832, 0.882)† 0.066
0.938 (0.921, 0.953)* 0.116 637 0.829 (0.808, 0.849) 0.007
0.946 (0.933, 0.959)* 0.253 645 0.843 (0.802, 0.884)† 0.163
0.948 (0.934, 0.960)* 0.130 647 0.858 (0.832, 0.882)† 0.04
mean EQ-5D score for the subgroup of respondents affected by the
n comparing respondents with no health condition vs. respondents
Appendix.
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543V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 3 9 – 5 4 5slightly by age for respondents aged over 40 years (Appendix,
Fig. A2 available at doi:10.1016/j.jval.2010.10.029). Conversely,
or the cohort (n  1358) with just arthritis/rheumatism/fibro-
itis and no other condition, compared to respondents with no
ealth condition, the average relative decrement on HRQoL in-
reased by age. When comparing the mean EQ-5D scores from
ohorts with just arthritis/rheumatism/fibrositis with the mean
Q-5D scores for cohorts with arthritis/rheumatism/fibrositis
lus any other condition, the confidence intervals of the mean
Q-5D scores did not overlap for the cohorts aged between 40
ears and 70 years only. All age- and condition-specific mean
Q-5D scores used in the analyses that are not discussed in the
rticle are provided in the online Appendix at: doi:10.1016/j.
val.2010.10.029.
Discussion
This study provides EQ-5D scores obtained from noninstitutional-
ized residents in England stratified by self-reported history of
prevalent health condition(s) and age (where sample sizes permit).
Our results suggest that data from the general population irre-
spective of health status could be used in place of condition spe-
cific data to represent the HSUVs associated with not having a
particular health condition in some analyses but not all. In partic-
ular, our analyses show that HSUVs from the general population
would not be appropriate for cohorts who have just one health
condition. In these instances, if the condition-specific data are not
available, age-stratified mean HSUVs from respondents who re-
port they have none of the prevalent health conditions could be
used.
Not surprisingly, the average decrement on HRQoL compared
to the condition-specific baseline was generally smaller for re-
spondents with a single health condition compared to respon-
dents with the same health condition plus any comorbidities. For
several conditions the decrement wasmore than halved. Amajor-
ity of analytic models use cohorts defined to match those in the
clinical studies used to represent the effectiveness of treatment.
Therefore the data fromcohortswith comorbidities are potentially
more relevant as few clinical data are derived from patients who
do not have any of the prevalent conditions, particularly in older
age cohorts. However, some clinical studies do impose strict ex-
0.4
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0.7
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0.9
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Respondents with no health condition All respondents irrespec
Fig. 1 – Mean EQ-5D scores (and 95% confidence inteclusion criteria relating to comorbidities. Consequently the clini-cal and HRQoL evidence and the cohort definitions used in eco-
nomic models should be considered carefully when selecting the
baseline HSUV used to estimate the benefits of treatments.
Our exploratory analyses suggest the decrements on HRQoL as-
sociated with health conditions are not constant across age. Some
conditionsshowedan increasing trendandothers showedadecreas-
ing trend. This may be due to the prevalence of comorbidities and
additional research in this area would be beneficial. In particular re-
search inhealthconditionsthathaveasubstantialeffectonHRQoLand
cohorts subgrouped by severity of conditionwould be interesting.
Although we found a strong trend for HSUVs to decrease by age
irrespective of health status, we observed a levelling or increase in
mean HRQoL in the age groups 65 to 70 years. This has also been
reported in data collected using several different preference-based
measures in the United States [10]. This could be caused by a rela-
tionship between HRQoL and all-cause mortality rates (people with
severe health conditions that have a large effect on HRQoL may be
more likely to die at a younger age than thosewith less severe health
conditions) followed by an increasing prevalence of comorbidities.
Additional research is required to support this hypothesis.
There are limitations with the data used in this study. In par-
ticular the health conditions are self-reported, and no information
was collected that could be used to determine either the duration
of the health condition or the severity of the condition. There was
a great deal of individual variation for respondents reporting the
same health condition and this could be partly attributable to the
wide range in severity of and duration of condition included
within a single subgroup. The coded conditions are not exhaustive,
and it is probable that some respondents had health conditions that
are not included in the analyses. As the conditions that are not iden-
tified are not prevalent, this is unlikely to affect our main findings.
The surveys did not sample people in nursing homes or other insti-
tutions who are likely to have lower HRQoL on average than those
residing in their own homes. This is more likely to have an effect on
the HSUVs for the older-aged cohorts, and it could be that the actual
average EQ-5D scores for these subgroups are lower than we report.
This may have an influence on the age-related trends in the decre-
ments for the different health conditions, and additional research in
this area would be interesting.
Some of the mean HSUVs for subgroups with a particular con-
dition are lower than the corresponding values for subgroups
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544 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 3 9 – 5 4 5health status, which initially appears counterintuitive. For the
analyses conducted on subgroups with just one health condition,
one possible explanation for higher HSUVs for the respondents
with a condition is that the average person in the general popula-
tionwill in fact have a lowerHSUVas the combined decrements on
HRQoL for the prevalent conditions could be larger than the dec-
rement for the single condition.
Decision analytic models of health care interventions re-
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compared to respondents without back problems/slipped di
disc/spine/neck and no other health condition compared to
next to data points for respondents who have the conditionquire a baseline HRQoL profile to accurately calculate the ben-efits of treatment. These data would ideally be derived from
respondents who do not have the exact definition of the health
condition(s) being modelled. When these data are not available,
this study provides a number of age and health condition strat-
ified HSUVs that can be used to assess the benefits of treatment
compared to an average person who does not have the condi-
tion. Our results suggest age-adjusted HSUVs from the general
population could be used as the baseline when modelling the
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.)benefits of treatment for individuals with comorbidities. How-
([
545V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 3 9 – 5 4 5ever, these data are not appropriate when modelling interven-
tions in patients with a single health condition. Our findings
require validation in additional data sets, and additional re-
search examining subgroups of patients with precisely defined
health conditions would be beneficial.
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